Considerations when treating high-grade pediatric glioma patients with immunotherapy.

ABSTRACT:

Introduction

Children with high-grade gliomas (pHGGs) represent a clinical population in substantial need of new therapeutic options given the inefficacy and toxicity of current standard-of-care modalities. Although immunotherapy has emerged as a promising modality, it has yet to elicit a significant survival benefit for pHGG patients. While preclinical studies address a variety of underlying challenges, translational clinical trial design and management also need to reflect the most updated progress and lessons from the field.

Areas covered

The authors will focus our discussion on the design of clinical trials, the management of potential toxicities, immune monitoring, and novel biomarkers. Clinical trial design should integrate appropriate patient populations, novel, and p

SUBMITTER: Crotty E 

PROVIDER: S-EPMC7880880 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature